Biocryst Pharmaceuticals Inc.

NASDAQ:BCRX  
9.11
+0.08 (+0.89%)
Other Pre-Announcement

BioCryst Reports First Quarter 2022 Financial Results And Upcoming Key Milestones

Published: 05/05/2022 11:37 GMT
Biocryst Pharmaceuticals Inc. (BCRX) - Biocryst Reports First Quarter 2022 Financial Results and Upcoming Key Milestones.
Q1 Loss per Share $0.40.
Orladeyo Net Revenue in 2022 Expected to Be No Less Than $250 Million.
Biocryst, on Bcx9930 Investigation, Says Believe Both Dose and Dosing Regimen Could Be Contributing Factors to Safety Signal We Have Observed.
By Q3 End, Co Plans to Discuss Approach to Resume Redeem Trials, Under a Revised Dosing Protocol, With Regulators.
For the Three Months Ended March 31, 2022, Total Revenues Were $49.9 Million, Compared to $19.1 Million in Q1 2021.
Expects to Provide an Updated Outlook on Full Year 2022 Operating Expenses.
If Bcx9930 Program Enrollment Resumes, Then Operating Expenses Likely to Be at Lower End of Previously Provided Range.
If Co Discontinues Bcx9930 Program, Operating Expenses for Year Would Be Lower Than Previous Range.